Brief: Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
15/05/2024 12:11
May 15 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES PROMISING NEW DATA FOR
PALAZESTRANT IN
COMBINATION WITH RIBOCICLIB PRESENTED AT THE 2024 ESMO BREAST
CANCER CONGRESS
* OLEMA PHARMACEUTICALS: ACROSS 50 TREATED PATIENTS,
PALAZESTRANT
(OP-1250) PLUS RIBOCICLIB WAS WELL TOLERATED WITH NO NEW SAFETY
SIGNALS
* OLEMA REPORTS 85% CBR IN BREAST CANCER DRUG STUDY
Source text for Eikon: ID:nGNX7ySDsv
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs